Effect of antifibrotics on short-term outcome after bilateral lung transplantation: A multicentre analysis

European Respiratory Journal

Volumn 51, Issue 6, 2018, Pages

  Lambers, Christopher ^a   Boehm, Panja M ^a   Lee, Silvia ^a   Ius, Fabio ^b   Jaksch, Peter ^a   Klepetko, Walter ^a   Tudorache, Igor ^b   Ristl, Robin ^a   Welte, Tobias ^b,c   Gottlieb, Jens ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c German Center for Lung Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; CORTICOSTEROID; HEMOGLOBIN; NINTEDANIB; PIRFENIDONE; STEROID; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ALLERGIC PNEUMONITIS; ARTIFICIAL VENTILATION; BRONCHUS STENOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EVENT FREE SURVIVAL; EXTRACORPOREAL OXYGENATION; EXTUBATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOTHORAX; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LETTER; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OPERATION DURATION; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VACUUM ASSISTED CLOSURE; WOUND INFECTION; CLINICAL TRIAL; EUROPE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; POSTOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY;

EUROPE; FEMALE; HUMANS; INDOLES; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PYRIDONES; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 85054655891     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00503-2018     Document Type: Letter

References (15)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
4. Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62: 62–66.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
6. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
7. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015; 16: 116.
8. European Medicines Agency. Ofev – nintedanib. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124 Date last updated: September 19, 2017. Date last accessed: September 23, 2017.
9. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396–400.
10. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoid Vasc Diffuse Lung Dis 1999; 16: 209–214.
11. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469–475.
12. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report – 2008. J Heart Lung Transplant 2008; 27: 957–969.
13. Valapour M, Paulson K, Smith JM, et al. OPTN/SRTR 2011 annual data report: lung. Am J Transplant 2013; 13: Suppl. 1, 149–177.
14. Leuschner G, Stocker F, Veit T, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant 2017 in press [https://doi.org/10.1016/j.healun.2017.07.002].
15. Delanote I, Wuyts WA, Yserbyt J, et al. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016; 16: 156.